semaglutide sales Oral (Rybelsus®) receives FDA approval for the treatment of type 2 diabetes The weight‑management market is shifting

The STEP-HFpEF trial randomised 529 patients with obesity (BMI 30 kg/m 2 ), HFpEF (left ventricular ejection fraction [LVEF] 45%) and New York Heart Association (NYHA) Class II symptoms to once-weekly subcutaneous semaglutide 2.4 mg or placebo

Larger, longer, and more diverse clinical studies are still needed to clarify safety, long-term outcomes, and appropriate use

however, compounded drugs are not FDA-approved, and their safety and efficacy are not validated

Methods: A structured narrative review of clinical trials, real-world observational studies, and contextual cardiovascular outcome analyses was conducted

They increase GLP-1 hormone levels